Anti-KIRD2 Subgroup Recombinant Antibody (Lirilumab) (CAT#: TAB-757)

Recombinant human monoclonal antibody expressed in CHO binding to human KIRD2 subgroup. Lirilumab is a human monoclonal antibody designed for the treatment of cancer.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Tested Data
  • Datasheet
  • MSDS
  • COA
ELISA

Figure 1 Anti-KIRD2 Subgroup Antibody (Lirilumab) (TAB-757) in ELISA

Figure 1 Anti-KIRD2 Subgroup Antibody (Lirilumab) (TAB-757) in ELISA

ELISA analysis of TAB-757 was performed by coating with KIR2DL1 Protein, Human, Recombinant (His Tag).
Blue line: TAB-757
Red line: Negative control

SDS-PAGE

Figure 2 Anti-KIRD2 Subgroup Recombinant Antibody (TAB-757) in SDS-PAGE

Figure 2 Anti-KIRD2 Subgroup Recombinant Antibody (TAB-757) in SDS-PAGE

SDS-PAGE analysis of TAB-757 in non-reduced (Lane 1) and reduced (Lane 2) conditions.

SEC-HPLC

Figure 3 Anti-KIRD2 Subgroup Recombinant Antibody (TAB-757) in HPLC

Figure 3 Anti-KIRD2 Subgroup Recombinant Antibody (TAB-757) in HPLC

HPLC analysis of TAB-757 shows the purity is>95%.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • IgG4 - kappa
  • Species Reactivity
  • Human
  • Applications
  • Suitable for use in Neut, ELISA, IF, IP, FuncS, FC, ICC and most other immunological methods.
  • CAS
  • 1000676-41-4
  • Generic Name
  • lirilumab
  • MW
  • 145.2 kDa
  • Related Disease
  • Acute myeloid leukemia (AML)

Product Property

  • Purity
  • >95.0%, determined by analysis by RP-HPLC & analysis by SDS-PAGE.
  • Storage
  • Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C.

Target

  • Alternative Names
  • lirilumab;1000676-41-4;IPH 2101;IPH2101;1-7F9;IPH 2102;IPH2102;BMS-986015;Killer-cell immunoglobulin-like receptors;KIRs;KIR2DL1/2/3

Related Resources

  • Biosimilar Overview
Please refer to Lirilumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Lirilumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Lirilumab"

Afuco™ Anti-KIRD2 ADCC Recombinant Antibody (Lirilumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant human monoclonal antibody expressed in CHO binding to human KIRD2 subgroup. Lirilumab is a human monoclonal antibody designed for the treatment of cancer.

See other products for "KIRD2"

Single-domain Antibody

CAT Product Name Application Type
NAB-1602-sdAb Recombinant Anti-Human KIRD2 VHH Single Domain Antibody WB, ICC, ChiP, FA, ELISA Llama VHH

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-757. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare